Janux Therapeutics (JANX) Stock Forecast: StockMap's 2-Week Call

JANX stock forecast: StockMap's model leans Underperform on Janux Therapeutics for the two weeks after the Nov 19 close, toward JANX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 6 two-week windows on JANX since Aug 21; by chance, a call on the same dates was right 59% of the time.

Janux Therapeutics last closed at $10.29, -0.19% on the session.

Against the IVW growth benchmark the position is +2.14% over the forecast window.

Janux Therapeutics' market cap is $629.60M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).

Where JANX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

30 daily calls for JANX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Janux Therapeutics in the 31st percentile on return on equity, where 100 is best.

Janux Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Janux Therapeutics as the 154th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Janux Therapeutics ranks 188th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Janux Therapeutics (JANX) — StockMap 2-week forecast & tracked accuracy